BioSpecifics Technologies Corp. to Present at the Stifel 2017 Healthcare Conference

LYNBROOK, N.Y., Nov. 7, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 3:30 p.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or at http://wsw.com/webcast/stifel10/bstc/.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. Endo is partnered with Paladin Labs in Canada for Dupuytren's Contracture. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-stifel-2017-healthcare-conference-300550517.html

SOURCE BioSpecifics Technologies Corp.

Copyright 2017 PR Newswire